RBC Capital Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $32
RBC Cuts Price Target on Moderna to $32 From $40, Keeps Sector Perform Rating
Bernstein Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $39
Brookline Capital Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $212
Citi Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $40
Moderna Analyst Ratings
JPMorgan Cuts Price Target on Moderna to $33 From $40, Maintains Underweight Rating
Bernstein Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $39
Bernstein Adjusts Price Target on Moderna to $39 From $45, Keeps Market Perform Rating
Citi Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $40
Moderna Analyst Ratings
Citigroup Initiates Moderna at Neutral With $40 Price Target
Moderna (MRNA) Receives a Hold From Berenberg Bank
Berenberg Cuts Moderna Price Target Amid 2025 Headwinds
Redburn Atlantic Adjusts Price Target on Moderna to $55 From $73, Maintains Neutral Rating
DBS Initiates Moderna(MRNA.US) With Hold Rating, Announces Target Price $35
Leerink Partners Maintains Moderna(MRNA.US) With Sell Rating, Announces Target Price $27
UBS Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $78
RBC Capital Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $40
RBC Capital Reiterates Sector Perform on Moderna, Maintains $40 Price Target